AVDL VS VALN Stock Comparison
Performance
AVDL100/100
100/100
AVDL returned 58.04% in the last 12 months. Based on SPY's performance of -21.06%, its performance is above average giving it a score of 100 of 100.
VALN10/100
10/100
VALN returned -6.85% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
AVDL80/100
80/100
5 analysts offer 12-month price targets for AVDL. Together, they have an average target of 10.67, the most optimistic target put AVDL at 12 within 12-months and the most pessimistic has AVDL at 9.
VALN
"Analyst Price Targets" not found for VALN
Sentiment
AVDL70/100
70/100
AVDL had a bullish sentiment score of 70.23% across Twitter and StockTwits over the last 12 months. It had an average of 6.78 posts, 3.03 comments, and 4.97 likes per day.
VALN
"Sentiment" not found for VALN
Technicals
AVDL11/100
11/100
AVDL receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
VALN71/100
71/100
VALN receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
Earnings
AVDL10/100
10/100
AVDL has missed earnings 7 times in the last 20 quarters.
VALN33/100
33/100
VALN has missed earnings 3 times in the last 20 quarters.
Profit
AVDL10/100
10/100
Out of the last 20 quarters, AVDL has had 1 profitable quarters and has increased their profits year over year on 1 of them.
VALN19/100
19/100
Out of the last 20 quarters, VALN has had 5 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
AVDL56/100
56/100
AVDL has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.
VALN59/100
59/100
VALN has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Avadel Pharmaceuticals plc Ordinary Share Summary
Nasdaq / AVDL
Healthcare
Drug Manufacturers - Specialty & Generic
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Valneva SE American Depositary Shares Summary
Nasdaq / VALN
Healthcare
Biotechnology
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare AVDL to other companies in the same or a similar industry.